KR20200010440A - 야누스 키나아제 저해제의 글루쿠로니드 프로드러그 - Google Patents

야누스 키나아제 저해제의 글루쿠로니드 프로드러그 Download PDF

Info

Publication number
KR20200010440A
KR20200010440A KR1020197037814A KR20197037814A KR20200010440A KR 20200010440 A KR20200010440 A KR 20200010440A KR 1020197037814 A KR1020197037814 A KR 1020197037814A KR 20197037814 A KR20197037814 A KR 20197037814A KR 20200010440 A KR20200010440 A KR 20200010440A
Authority
KR
South Korea
Prior art keywords
compound
formula
methyl
alkyl
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020197037814A
Other languages
English (en)
Korean (ko)
Inventor
다니엘 디. 롱
도나 에이.에이. 윌턴
맨디 루
라이언 허드슨
패트릭 제이. 브라실
Original Assignee
세라밴스 바이오파마 알앤디 아이피, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 filed Critical 세라밴스 바이오파마 알앤디 아이피, 엘엘씨
Publication of KR20200010440A publication Critical patent/KR20200010440A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020197037814A 2017-05-23 2018-05-22 야누스 키나아제 저해제의 글루쿠로니드 프로드러그 Withdrawn KR20200010440A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762509847P 2017-05-23 2017-05-23
US62/509,847 2017-05-23
PCT/US2018/033818 WO2018217700A1 (en) 2017-05-23 2018-05-22 Glucuronide prodrugs of janus kinase inhibitors

Publications (1)

Publication Number Publication Date
KR20200010440A true KR20200010440A (ko) 2020-01-30

Family

ID=62621001

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197037814A Withdrawn KR20200010440A (ko) 2017-05-23 2018-05-22 야누스 키나아제 저해제의 글루쿠로니드 프로드러그

Country Status (14)

Country Link
US (2) US10745405B2 (https=)
EP (1) EP3609899A1 (https=)
JP (1) JP2020520955A (https=)
KR (1) KR20200010440A (https=)
CN (1) CN110662747A (https=)
AU (1) AU2018273866B2 (https=)
BR (1) BR112019024509A2 (https=)
CA (1) CA3063963A1 (https=)
IL (1) IL270693A (https=)
MX (1) MX2019014054A (https=)
NZ (1) NZ759764A (https=)
PH (1) PH12019502605A1 (https=)
RU (1) RU2019142472A (https=)
WO (1) WO2018217700A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111094314B (zh) * 2018-08-15 2022-08-12 江苏豪森药业集团有限公司 含有葡糖苷酸衍生物jak抑制剂的前药及其制备方法和应用
BR112021026517A2 (pt) 2019-06-28 2022-05-10 Kymera Therapeutics Inc Degradadores de irak e usos dos mesmos
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US12551564B2 (en) 2019-12-10 2026-02-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2021127190A1 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN111196831B (zh) * 2020-01-20 2023-05-09 山西医科大学 一种呋喃酚葡萄糖醛酸结合物的制备方法
CN116867494A (zh) 2021-02-15 2023-10-10 凯麦拉医疗公司 Irak4降解剂和其用途
EP4384173A1 (en) * 2021-08-12 2024-06-19 Sun Pharmaceutical Industries, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
WO2023155905A1 (zh) * 2022-02-21 2023-08-24 上海岸阔医药科技有限公司 化合物及其用途
CN119923257A (zh) * 2022-04-15 2025-05-02 密歇根大学董事会 Jak抑制剂类似物、制剂及其用途
CN115073543B (zh) * 2022-07-20 2022-11-15 北京普祺医药科技股份有限公司 一种jak抑制剂的化合物前药及其制备与应用
EP4637724A1 (en) 2022-12-22 2025-10-29 KRKA, d.d., Novo mesto Veterinary composition comprising oclacitinib
WO2024148049A1 (en) * 2023-01-04 2024-07-11 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993022334A1 (en) * 1992-05-04 1993-11-11 Sri International Pharmaceutical compositions and methods for colonic delivery of corticosteroids
US5811388A (en) 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
EP1382339B1 (en) 1999-12-10 2007-12-05 Pfizer Products Inc. Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
US7798257B2 (en) 2004-04-30 2010-09-21 Smith International, Inc. Shaped cutter surface
EP2455382B1 (en) 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
JP4884570B2 (ja) 2008-08-20 2012-02-29 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
KR101921850B1 (ko) * 2009-10-09 2018-11-23 인사이트 홀딩스 코포레이션 3-（4-（7Ｈ-피롤로〔2,3-ｄ〕피리미딘-4-일）-1Ｈ-피라졸-1-일）-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체
EP2695617B1 (en) 2009-12-23 2019-01-09 Glycomyr Inc. Vitamin D glycosides and sulfates for treating intestinal diseases
CN102724967A (zh) 2009-12-31 2012-10-10 安龙制药公司 包括可释放的脲连接体的含芳香胺化合物的聚合缀合物
JP2013518882A (ja) 2010-02-05 2013-05-23 ファイザー・インク ＪＡＫ阻害剤としてのピロロ［２，３−ｄ］ピリミジン尿素化合物
JP2016528174A (ja) 2013-05-31 2016-09-15 セルリアン・ファーマ・インコーポレイテッド 治療的送達用のシクロデキストリンベースのポリマー
ES2784523T3 (es) 2015-11-24 2020-09-28 Theravance Biopharma R&D Ip Llc Profármacos de un compuesto inhibidor de JAK para el tratamiento de enfermedades inflamatorias gastrointestinales
CN106496233B (zh) * 2016-09-26 2018-05-15 东南大学 吡咯并嘧啶类化合物、其制备方法及其用途

Also Published As

Publication number Publication date
WO2018217700A1 (en) 2018-11-29
US10745405B2 (en) 2020-08-18
MX2019014054A (es) 2020-02-05
US20180339990A1 (en) 2018-11-29
RU2019142472A3 (https=) 2021-09-23
AU2018273866B2 (en) 2021-09-30
NZ759764A (en) 2022-07-01
EP3609899A1 (en) 2020-02-19
CA3063963A1 (en) 2018-11-29
US20210032250A1 (en) 2021-02-04
JP2020520955A (ja) 2020-07-16
IL270693A (en) 2020-01-30
CN110662747A (zh) 2020-01-07
PH12019502605A1 (en) 2020-10-26
AU2018273866A1 (en) 2019-12-19
RU2019142472A (ru) 2021-06-24
BR112019024509A2 (pt) 2020-06-23

Similar Documents

Publication Publication Date Title
KR20200010440A (ko) 야누스 키나아제 저해제의 글루쿠로니드 프로드러그
US10472366B2 (en) Glucuronide prodrugs of tofacitinib
AU2016359494B2 (en) Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease
CN109422752B (zh) 一类具有抑制并降解布鲁顿酪氨酸蛋白激酶Btk活性的化合物
US9688654B2 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
CN109516989B (zh) 一类抑制并降解cdk的化合物
SG176042A1 (en) 7-aza-spiro[3.5]nonane-7-carboxylate derivatives, preparation thereof, and therapeutic use thereof
CA2737038A1 (en) Amide compounds, compositions and uses thereof
KR20130046436A (ko) 안드로겐 수용체 길항제, 항암제로서 사이클릭 n,n''-다이아릴티오우레아 및 n,n''-다이아릴우레아, 이의 제조방법 및 이의 용도
CN117466868A (zh) 双重magl和faah抑制剂
KR20240021239A (ko) Cdk 키나아제 억제제로 사용되는 화합물 및 이의 용도
CN117756812A (zh) 一类prmt5抑制剂及其用途
WO2013192610A2 (en) Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
KR20250164854A (ko) 치환된 인다졸 프로피온산 유도체 화합물 및 ampk 활성제로서의 이의 용도
WO2016107227A1 (zh) 吡咯酰胺类化合物及其制备方法与用途
CN113166148B (zh) 作为cdk-hdac双通路抑制剂的杂环化合物
US20210238136A1 (en) Azetidine derivative, and prodrug thereof
EP3968994B1 (en) Abhd12 inhibitors and methods of making and using same
CN118772107B (zh) Hdac抑制剂及其用途
WO2026060256A1 (en) Sting inhibitors and uses thereof
WO2025255442A1 (en) Trim21-targeted compounds and uses thereof
KR20250117821A (ko) Hdac 억제제 및 이의 용도
NZ717556A (en) Spirocyclic compounds as tryptophan hydroxylase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191220

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210429

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20211013

WITB Written withdrawal of application